Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607686 | 0.91 | AKT1 (0.55) | AKT1AKT2 | |
| SCHEMBL1607772 | 0.90 | AKT1 (0.56) | AKT1AKT2 | |
| SCHEMBL1607788 | 0.89 | AKT1 (0.54) | AKT1AKT2 | |
| SCHEMBL1607059 | 0.89 | AKT1 (0.54) | AKT1AKT2 | |
| SCHEMBL1607254 | 0.89 | AKT1 (0.54) | AKT1AKT2 | |
| SCHEMBL1608693 | 0.88 | AKT1 (0.60) | AKT1AKT2 | |
| SCHEMBL1607165 | 0.87 | AKT1 (0.56) | AKT1AKT2 | |
| SCHEMBL1607962 | 0.87 | AKT1 (0.56) | AKT1AKT2 | |
| SCHEMBL1607785 | 0.86 | AKT1 (0.56) | AKT1AKT2 | |
| SCHEMBL2027037 | 0.86 | AKT1 (0.49) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2299825-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | claimed |
| US-8536193-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2299825-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, AKT1S1, AKT1 | AKT1 3/4885AKT2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.